News
Bayer is positive of future growth in its pharmaceuticals pipeline, with five key drugs expected to reach annual peak sales of €5.5 billion. Bayer’s Management Board Chairman, Dr. Marijn Dekkers, believes that the pharmaceutical company’s five most…
Today is World Diabetes Day and pharmaceutical companies, Sanofi and Boehringer Ingelheim have announced their plans to support patients with type 1 and type 2 diabetes worldwide. To coincide with World Diabetes Day, Sanofi has announced its plans to collaborate with…
Prostate Cancer UK and over a dozen other cancer charities have published a report highlighting their recommendations for the UK government to consider when discussing a new drug pricing system. A coalition of leading cancer charities has criticized the UK government for shutting patients out of crucial…
Celgene shares rise by up to 9.7% after the biopharma company reported that phase 3 trials of Abraxane met its primary endpoints. Global biopharmaceutical company, Celgene, has announced that its phase 3 clinical trials of Abraxane have shown…
A generic version of Pfizer’s Revatio to treat pulmonary arterial hypertension has been approved for use in the US by the FDA. Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received approval from the US FDA for its…
Mid-stage clinical trials found that 69% patients on Boehringer Ingelheim’s hepatitis C drug were free of the virus 12 and 24 weeks following the end of treatment. Boehringer Ingelheim is to begin phase 3 clinical trials of its hepatitis C drug following promising phase…
GSK’s malaria vaccine has been evaluated in late-stage clinical trials. GlaxoSmithKline’s experimental malaria vaccine, RTS,S, has proved only 30% effective when administered to babies, as…
UK’s governing body, NICE, has decided to stop its recommendation of asthma drug, Xolair, following inconsistencies in clinical trial data. Britain’s National Institute for Health and Clinical Excellence (NICE) has decided to withdraw its recommendation for…
GSK and XenoPort mutually agree to end their collaboration on restless leg syndrome drug, Horizant. GSK and XenoPort have announced mutual termination of their collaboration concerning restless leg…
